Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

Ahluwalia, M., Ali, M. A., Joshi, R. S., Park, E. S., Taha, B., McCutcheon, I., Chiang, V., Hong, A., Sinclair, G., Bartek, J., & Chen, C. C. (2021). An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status. Neuro-Oncology Advances, 3(1), vdaa152. https://doi.org/10.1093/noajnl/vdaa152

CBE

MLA

Vancouver

Author

Ahluwalia, Manmeet ; Ali, Mir A ; Joshi, Rushikesh S ; Park, Eun Suk ; Taha, Birra ; McCutcheon, Ian ; Chiang, Veronica ; Hong, Angela ; Sinclair, Georges ; Bartek, Jiri ; Chen, Clark C. / An integrated disease-specific graded prognostic assessment scale for melanoma : contributions of KPS, CITV, number of metastases, and BRAF mutation status. I: Neuro-Oncology Advances. 2021 ; Bind 3, Nr. 1. s. vdaa152.

Bibtex

@article{b1b60863f01f4c8fbc216d05475d066f,
title = "An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status",
abstract = "Background: Stereotactic radiosurgery (SRS) remains a mainstay therapy in the treatment of melanoma brain metastases (BM). While prognostic scales have been developed for melanoma patients who underwent SRS treatment for BM, the pertinence of these scales in the context of molecularly targeted therapies remains unclear.Methods: Through a multi-institutional collaboration, we collated the survival patterns of 331 melanoma BM patients with known BRAF mutation status treated with SRS. We established a prognostic scale that was validated in an independent cohort of 174 patients. All patients with BRAF mutations in this series were treated with BRAF inhibitors. Prognostic utility was assessed using Net Reclassification Index (NRI > 0) and integrated discrimination improvement (IDI) metrics.Results: In a multivariate Cox proportional hazards model, BRAF mutation status, KPS, number of metastases, and cumulative intracranial tumor volume (CITV) independently contributed to survival prognostication for melanoma patients with SRS-treated BM (P < .05 for all variables). These variables were incorporated into a prognostic scale using the disease-specific graded prognostic assessment (ds-GPA) framework. This integrated melanoma ds-GPA scale was validated in 2 independent cohorts collated through a multi-institutional collaboration. In terms of order of prognostic importance, BRAF mutation status exerted the greatest influence on survival, while KPS, the number of metastases, and CITV exhibited comparable, lesser impacts.Conclusions: Optimal survival prognostication for SRS-treated patients with melanoma BM requires an integrated assessment of patient characteristics (KPS), tumor characteristics (CITV and number of metastases), and the mutational profile of the melanoma (BRAF mutation status).",
author = "Manmeet Ahluwalia and Ali, {Mir A} and Joshi, {Rushikesh S} and Park, {Eun Suk} and Birra Taha and Ian McCutcheon and Veronica Chiang and Angela Hong and Georges Sinclair and Jiri Bartek and Chen, {Clark C}",
note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.",
year = "2021",
month = jan,
day = "29",
doi = "10.1093/noajnl/vdaa152",
language = "English",
volume = "3",
pages = "vdaa152",
journal = "Neuro-Oncology Advances",
issn = "2632-2498",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - An integrated disease-specific graded prognostic assessment scale for melanoma

T2 - contributions of KPS, CITV, number of metastases, and BRAF mutation status

AU - Ahluwalia, Manmeet

AU - Ali, Mir A

AU - Joshi, Rushikesh S

AU - Park, Eun Suk

AU - Taha, Birra

AU - McCutcheon, Ian

AU - Chiang, Veronica

AU - Hong, Angela

AU - Sinclair, Georges

AU - Bartek, Jiri

AU - Chen, Clark C

N1 - © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

PY - 2021/1/29

Y1 - 2021/1/29

N2 - Background: Stereotactic radiosurgery (SRS) remains a mainstay therapy in the treatment of melanoma brain metastases (BM). While prognostic scales have been developed for melanoma patients who underwent SRS treatment for BM, the pertinence of these scales in the context of molecularly targeted therapies remains unclear.Methods: Through a multi-institutional collaboration, we collated the survival patterns of 331 melanoma BM patients with known BRAF mutation status treated with SRS. We established a prognostic scale that was validated in an independent cohort of 174 patients. All patients with BRAF mutations in this series were treated with BRAF inhibitors. Prognostic utility was assessed using Net Reclassification Index (NRI > 0) and integrated discrimination improvement (IDI) metrics.Results: In a multivariate Cox proportional hazards model, BRAF mutation status, KPS, number of metastases, and cumulative intracranial tumor volume (CITV) independently contributed to survival prognostication for melanoma patients with SRS-treated BM (P < .05 for all variables). These variables were incorporated into a prognostic scale using the disease-specific graded prognostic assessment (ds-GPA) framework. This integrated melanoma ds-GPA scale was validated in 2 independent cohorts collated through a multi-institutional collaboration. In terms of order of prognostic importance, BRAF mutation status exerted the greatest influence on survival, while KPS, the number of metastases, and CITV exhibited comparable, lesser impacts.Conclusions: Optimal survival prognostication for SRS-treated patients with melanoma BM requires an integrated assessment of patient characteristics (KPS), tumor characteristics (CITV and number of metastases), and the mutational profile of the melanoma (BRAF mutation status).

AB - Background: Stereotactic radiosurgery (SRS) remains a mainstay therapy in the treatment of melanoma brain metastases (BM). While prognostic scales have been developed for melanoma patients who underwent SRS treatment for BM, the pertinence of these scales in the context of molecularly targeted therapies remains unclear.Methods: Through a multi-institutional collaboration, we collated the survival patterns of 331 melanoma BM patients with known BRAF mutation status treated with SRS. We established a prognostic scale that was validated in an independent cohort of 174 patients. All patients with BRAF mutations in this series were treated with BRAF inhibitors. Prognostic utility was assessed using Net Reclassification Index (NRI > 0) and integrated discrimination improvement (IDI) metrics.Results: In a multivariate Cox proportional hazards model, BRAF mutation status, KPS, number of metastases, and cumulative intracranial tumor volume (CITV) independently contributed to survival prognostication for melanoma patients with SRS-treated BM (P < .05 for all variables). These variables were incorporated into a prognostic scale using the disease-specific graded prognostic assessment (ds-GPA) framework. This integrated melanoma ds-GPA scale was validated in 2 independent cohorts collated through a multi-institutional collaboration. In terms of order of prognostic importance, BRAF mutation status exerted the greatest influence on survival, while KPS, the number of metastases, and CITV exhibited comparable, lesser impacts.Conclusions: Optimal survival prognostication for SRS-treated patients with melanoma BM requires an integrated assessment of patient characteristics (KPS), tumor characteristics (CITV and number of metastases), and the mutational profile of the melanoma (BRAF mutation status).

U2 - 10.1093/noajnl/vdaa152

DO - 10.1093/noajnl/vdaa152

M3 - Journal article

C2 - 33506199

VL - 3

SP - vdaa152

JO - Neuro-Oncology Advances

JF - Neuro-Oncology Advances

SN - 2632-2498

IS - 1

ER -

ID: 64686487